(Q37147755)

18 August 2017

1 reference

title

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond (English)

1 reference

18 August 2017

1 reference

1

Marc Ladanyi

1 reference

18 August 2017

2

William Pao

1 reference

18 August 2017

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

21 Suppl 2

1 reference

18 August 2017

S16-22

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.3801018

18 August 2017

0 references

cites work

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Assessing EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR mutations in small-cell lung cancers in patients who have never smoked.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Mutations of epidermal growth factor receptor andK-rasgenes in adenosquamous carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3801018

7 January 2021

10.1038/MODPATHOL.3801018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18437168